Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Wharton, Sean, Astrup, Arne, Endahl, Lars, Lean, Michael EJ, Satylganova, Altynai, Skovgaard, Dorthe, Wadden, Thomas A and Wilding, John PH ORCID: 0000-0003-2839-8404
(2021) Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. INTERNATIONAL JOURNAL OF OBESITY, 45 (5). pp. 923-933.


O'Neil, Patrick M, Aroda, Vanita R, Astrup, Arne, Kushner, Robert, Lau, David CW, Wadden, Thomas A, Brett, Jason, Cancino, Ana-Paula and Wilding, John PH ORCID: 0000-0003-2839-8404
(2017) Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. DIABETES OBESITY & METABOLISM, 19 (11). pp. 1529-1536.


Wilding, John PH ORCID: 0000-0003-2839-8404, Batterham, Rachel L, Calanna, Salvatore, Davies, Melanie, Van Gaal, Luc F, Lingvay, Ildiko, McGowan, Barbara M, Rosenstock, Julio, Tran, Marie TD, Wadden, Thomas A
et al (show 4 more authors) (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEW ENGLAND JOURNAL OF MEDICINE, 384 (11). pp. 989-1002.


Kushner, Robert F, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Garvey, W Timothy, Goldman, Bryan, Lingvay, Ildiko, Thomsen, Mette, Wadden, Thomas A, Wharton, Sean
et al (show 2 more authors) (2020) Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. OBESITY, 28 (6). pp. 1050-1061.


Wilding, John PH ORCID: 0000-0003-2839-8404, Batterham, Rachel L, Davies, Melanie, Van Gaal, Luc F, Kandler, Kristian, Konakli, Katerina, Lingvay, Ildiko, McGowan, Barbara M, Oral, Tugce Kalayci, Rosenstock, Julio
et al (show 4 more authors) (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. DIABETES OBESITY & METABOLISM, 24 (8). pp. 1553-1564.

This list was generated on Sat Aug 19 15:31:44 2023 BST.